The Longevity Reality Radar
46 approaches, rated by evidence.

Lenacapavir PrEP (Yeztugo)

Lenacapavir twice-yearly PrEP (Yeztugo). Infectious disease. Reviewed Jul 2026.

Randomised trials showed zero HIV infections among more than 2,100 women and about 96% lower incidence in a second trial.

Stage
Approved
Rung: Available now. Approved or established. Usable today, with a clinician.
Evidence grade
A
outcome RCTs
Randomised outcome data in people. How grades work.

What it is

A long-acting capsid inhibitor given as a subcutaneous injection just twice a year to prevent HIV.

The evidence

PURPOSE 1: zero infections among 2,100+ women; PURPOSE 2: ~96% reduction in incidence. FDA-approved for PrEP (June 2025); WHO-recommended; PEPFAR rolling out in high-burden countries in 2026.

What you can do today

This is available today. Whether it suits you depends on your health, your other medicines and your risks, so discuss it with a clinician who knows your history before starting or changing anything.

Sources

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Infectious disease

  • HIV functional cureGrade C, early human, mice. Preclinical, early human work.Reservoir reduction in early human work and viral suppression in mice, still far from a routine cure.